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Abstract: The process of informed consent remains a constant challenge in clinical research. The aim of the
present study was to evaluate the understanding of researchers and members of Institutional Review Boards (IRBs)
regarding the essential elements of an Informed Consent Form (ICF) as required by internationally recognized
regulations. Using eight case studies to illustrate basic ethical elements, the study involved 107 participants,
mainly from the Asia Pacific and African regions. The results showed that most of the participants had general
knowledge regarding the essential elements required in an ICF. However, the issues of confidentiality of data and
payment for study participation proved to be problematic for some participants, accounting for 35% and 28% of all
incorrect answers respectively. This suggests that participants’ understanding of the underlying concepts of the
required ICF elements is limited. Ethical training of researchers and IRB members, particularly in the Asia Pacific
and African regions, concerning valid informed consent is still needed.
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INTRODUCTION
The process of informed consent is widely recognized
as a necessary step in health-related research involving
human subjects. It is a process that is emphasized in the
Nuremberg Code [1] in response to the horrific and unethi-
cal experiments committed during World War II. The Code
stresses the importance of voluntary participation of
human subjects in research as well as the ethical responsi-
bilities of investigators. In 1979, the Belmont Report [2]
defined three basic ethical principles for biomedical re-
search. “Respect for Persons” is one of the principles men-
tioned and addresses the topic of informed consent. The
report further identifies three elements that are required for
consent to be valid: (1) sufficient relevant information for
decision making, (2) comprehension, and (3) voluntari-
ness. In other words, for a participant’s consent to be valid,
the participant should have received sufficient relevant in-
formation, should adequately understand the information
provided, and should arrive at a decision without being
subjected to coercion or undue influence. In 1996, the
International Conference on Harmonization (ICH) of Good
Clinical Practice (GCP) [3] was published as a collabora-
tive effort between Japan, the EU and the US in an attempt
to globally harmonize good clinical practice. The ICH
GCP sets out 20 basic essential elements that should be in-
cluded in an informed consent form (ICF) (see Table 1) as
well as how the informed consent should be documented.
Although the informed consent process is recognized
as an essential requirement in clinical research, in practice
it is still far from fully realizing the principle of Respect
for Persons [4–6]. The ICH GCP indicates that it is the re-
sponsibility of researchers to develop an ICF which in-
cludes sufficient relevant information for a potential
research participant’s decision making, while it is the role
of the Institutional Review Board (IRB) or Independent
Ethics Committee (IEC) to review such an ICF and the in-
formed consent process to ensure the obtainment of valid
consent [3]. As such it becomes essential, in the pursuit of
valid consent, that there is a good understanding of the
concepts underlying the essential ICF elements required by
internationally recognized guidelines and regulations.
The aim of the present study was to evaluate the un-
derstanding of researchers and IRB/IEC members concern-
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ing the essential elements required in an ICF in order to
identify issues that need to be addressed, as well as to im-
prove the competency of researchers and IRB/IEC
members in obtaining valid consent. Although the interna-
tionally recognized sources mentioned above have contrib-
uted to the discussion of inform consent, this paper will
mainly focus on the elements of an ICF provided by the
ICH GCP [3] and the US Regulation (45 CFR 46.116) [7],
because the majority of clinical trials currently being con-
ducted are governed by these two documents (see Table 1).
METHODS
Eight case studies and questions were developed
based on non-study-specific elements required by the ICH
GCP [3] and the US Regulation [7] (see Table 1). The case
studies were designed so that each case would illustrate
one of eight basic ethical issues in clinical research. Case
study one focuses on the experimental nature of the study,
case study two on the right of research subjects to refuse to
participate in the study, three on subjects’ right to with-
draw from the study, four on the confidentiality of data,
five on the limits of confidentiality, six on the payment for
Table 1. Elements required in an informed consent form based on ICH GCP and US Regulation
ICH GCP E6 (4.8.10) [3] US Regulation (45 CRF 46.116) [7]
Non-study-specific required elements
– Recognition that the trial involves research.
– The compensation of the subject if any trial-related injury
occurs.
– The anticipated payment as prorated, if any, to the subject for
trial participation.
– The voluntariness of the subject’s participation, including the
right of the subject to refuse to participate and right of the subject
to withdraw from the trial, at any time.
– The confidentiality of records identifying the subject.
– The limits of the confidentiality of records: the monitor(s), the
auditor(s), the IRB/IEC and the regulatory authority(ies) will be
granted direct access to the records for verification of the study
procedures.
– The contact person(s) for further information.
Non-study-specific basic elements required
– A statement that the study involves research.
– An explanation of the extent of the confidentiality of
records identifying the subject.
– An explanation of any compensation and any available
treatments if injury occurs during study participation.
– An explanation of appropriate contact persons for
answering pertinent questions about the study.
– A statement that the subject’s study participation is
voluntary: (1) right of the subject to refuse from study
participation and (2) right of the subject to discontinue from
study participation at any time.
Study-specific elements
– The purpose of the trial.
– The trial treatment(s).
– The trial procedures to be followed.
– The subject’s responsibilities.
– Identification of any aspects of the trial which are
experimental.
– The foreseeable risks or inconveniences to the subject.
– The reasonably expected benefits.
– The available alternative procedure(s) or course(s) of
treatment.
– The anticipated expenses, if any, to the subject for trial
participation.
– Provision of that the new available findings that may be
relevant to the subject’s willingness to continue participation in
the trial will be informed to the subject.
– The foreseeable circumstances and/or reasons under which the
subject’s participation may be terminated without the subject’s
consent.
– The expected duration of the subject’s participation in the trial.
– The approximate number of subjects involved in the trial.
Study-specific basic elements required
– An explanation of the purposes of the study and the
expected duration of the subject’s participation.
– A description of the procedures to be followed and
identification of any procedures which are experimental.
– A description of any foreseeable risks or discomforts to the
subject.
– A description of any direct and/or indirect benefits to the
subject.
– A disclosure of alternative procedures or courses of
treatment, if any.
 
Study-specific additional elements required
– A statement of possibly unforeseeable risks to the subject or
to the embryo or fetus.
– An explanation of any anticipated circumstances under
which the subject’s participation may be terminated by the
investigator without regard to the subject’s consent.
– A description of the anticipated expenses, if any, to the
subject for study participation.
– An explanation of the consequences of withdrawal from
study participation by the subject.
– A statement that, if any, significant new information that
may be relevant to the subject’s willingness to continue
participation will be provided during the study.
– The approximate number of subjects involved in the study.
ICH GCP, International Conference on Harmonization of Good Clinical Practice; IRB, Institutional Review Board; IEC,
Independent Ethics Committee.
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Table 2. The questionnaire containing eight short case studies: each case study followed by a question with four multiple-choice
answers
Ethical elements Short case studies and answer choices
Recognition that the study
involves research
Mr. Cahill is invited to participate in Phase I Clinical Study. This study aims to test a new drug in healthy volunteers. The
new drug has never been used in humans. Which of the following choices is true?
A. This study is a research study to test a new drug for the first time in humans.
B. This study is part of a teaching course for medical students to learn how to give drugs to patients.
C. This study is part of medical treatment that is expected to treat Mr. Cahill’s underlying disease.
D. This study is part of hospital regulation to test drugs used in the hospital once a year.
CORRECT ANSWER: A
Right of the subject to
refuse to participate in
research
Ms. Jones is a secretary in the hospital. She is being invited to participate in a research study. This study will test a new
drug in healthy volunteers. She worries about adverse effects from the new drug, so she does not want to take part in this
study. What can she do?
A. She has the right to refuse to participate in this study.
B. She must participate in this study because it is the duty of healthy people to contribute to the development of new
drugs for patients.
C. She cannot refuse to participate in the study because she works in this hospital. If she refuses, her boss may not be
pleased.
D. She should not worry about adverse effects from the study drug since the research team specializes in related
research. She will be closely observed.
CORRECT ANSWER: A
Right of the subject to
withdraw from the study
Mr. Knight was invited to participate in a research study. After being informed of all aspects of the research study, he was
willing to participate in the study and signed the consent form. However, when he went home, his wife did not agree with
him regarding his participation in such a study. Can he withdraw from study participation?
A. He cannot because he signed the consent form.
B. He can tell the research team and withdraw from the study.
C. He can but he has to pay some penalty because he signed the consent form.
D. He can but he has to find another volunteer to participate in this study in his place.
CORRECT ANSWER: B
The confidentiality of data Ms. Christine decided to participate in a research study. She is 30 years old. During the study, the research team collected
her personal information and blood samples for research purposes. At the end of the study, her father would like to see
her health data from this study due to safety concerns for his daughter. Can her father see her data from this study?
A. Yes, he can because he is her father. In general, parents have the right to see their son/daughter’s data.
B. Yes, he can because it was one of the aims of the study to distribute data from the study to the public.
C. No, he cannot because he is not an academic person. Only academic persons will be allowed to access the data for
academic purpose.
D. No, he cannot because the data from the research study are kept confidential.
CORRECT ANSWER: D
Authority of persons who
can access the data
Dr. John is an auditor from XXX company, which sponsors the Phase I Clinical Trial. After the study finishes, he would
like to get access to the data for verification. Can he see the data in this study?
A. No, he cannot because the data will be kept confidential. No one but the research team can see these data.
B. No, he cannot because only the representatives from the National Authority for the drug used and Institutional
Review Board (IRB) members can see these data.
C. Yes, he can because he is a representative of the sponsor who has a responsibility to ensure the accuracy of the data.
D. Yes, he can because the study aims to distribute the data obtained from study to public. Therefore, everyone can see
these data.
CORRECT ANSWER: C
Prorated payment for study
participation
Ms. Catherine decided to participate in a research study. She must make four visits in total to see the research team. She
will receive payment for study participation. When will she receive this payment?
A. After signing the informed consent form.
B. After her personal information and blood samples have been collected at the screening visit.
C. After finishing study participation at the end of the study.
D. Every visit that she comes as prorated payment
CORRECT ANSWER: D
Compensation in case of
any injury directly result-
ing from study participation
Mr. Adam participated in Phase I Clinical Trial. Two days after taking an investigational drug, he had diarrhea many
times. He was admitted to the hospital for two days. The cost of treatment was 500 US dollars. Who will pay for this
treatment?
A. Mr. Adam
B. Mr. Adam and the researcher
C. The sponsor of the study
D. The doctor who treated his illness
CORRECT ANSWER: C
Research contact person Ms. Caroline decided to take part in Phase I Clinical Trial. The research staff told her that the study will start next
Monday. By Monday, she has a high fever. She is not sure whether she can take any medication or not. Which of the
following choices is the best choice for her?
A. She should call the contact person named on the information sheet of the study and ask for suggestions.
B. She must not take any treatment since the information sheet states clearly that she cannot take any medication one
week prior to the start of her participation in the study.
C. She should use warm towels to absorb the heat from her body and ask the research team on Monday about what to do.
D. She should ask another participant who has experience in study participation.
CORRECT ANSWER: A
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study participation, seven on the compensation in case of
any injury incurred during study participation, and case
eight on the contact person providing further information
during the study (see Table 2).
Each question was designed to reflect the area we
considered of most concern regarding that particular ele-
ment. Following each scenario, there is a question with
four multiple-choice answers intended to test the partici-
pants’ understanding of the underlying ethical issues pre-
sented in the given scenario. The developed case studies
and answer choices were reviewed by two independent ex-
perts whose comments were then integrated into the final
version of the case studies and questions (see Table 2). The
assessment of knowledge on the above-mentioned basic
ethical issues was performed in three groups of partici-
pants on three separate occasions. The first group consisted
of researchers in the field of product research and develop-
ment who attended the 7th International Diploma Course
of Research and Development of Products to Meet Public
Health Needs (October 29th–November 9th, 2013) (n =
26). The second group was the participants who attended
the 13th International Annual FERCAP (the Forum for
Ethical Review Committees in Asia and the Western Pacif-
ic) Conference in Bali, Indonesia (November 18th–20th,
2013) (n = 69). The last group was PhD candidates or re-
searchers at the Institute of Tropical Medicine (NEKKEN),
Nagasaki University in 2013 (n = 12). For the first and sec-
ond groups of participants, the questionnaires were distrib-
uted prior to the training course on informed consent. The
questionnaires were answered in an anonymous manner
and collected by a qualified individual who had no teacher-
student/trainer-trainee relationship with the respondents.
Each correct answer was worth 1 point, making the perfect
score a total of 8 points.
The data were analyzed using SPSS version 16.0. The
distribution of data was tested using Kolmogorov-Smirnov
statistics. The frequency of incorrect answers in each ques-
tion was identified and presented as a percentage of total
incorrect answers.
RESULTS
A total of 107 individuals from 20 countries partici-
pated in the study. The majority came from Asia and the
Western Pacific region (China, India, Indonesia, Japan,
Nepal, the Philippines, Sri Lanka, Thailand and Vietnam).
Most of the remaining participants came from the African
region (Algeria, Botswana, Ethiopia, Guinea, Kenya,
Nigeria, Sudan and Uganda), and only four participants
came from American and South American regions
(Bolivia, Guatemala and USA). Each participant came
from one of four backgrounds: researcher, medical doctor,
PhD candidate, or IRB/IEC member.
The collected data were not normally distributed, thus
the results were presented as a median (Fig. 1). The me-
dian score was 7 (interquartile, 6–8). Thirty-five partici-
pants (32.7%) had a perfect score (score = 8). Five
participants (4.7%) had a score of less than 4. No signifi-
cant difference of score was observed among the three
groups of participants.
There were a total of 139 incorrect answers from the
107 participants; the frequency of incorrect answers for
each question is presented in Figure 2. The most common
incorrect answer was in case study 5, which describes the
authority of research-related persons to access the data.
This question accounted for 35% of all the incorrect an-
swers (49/139). The second most common mistake was in
case study 6, describing the need for prorated payment,
which accounted for 28% of all the incorrect answers
(38/139). Most of the participants who made mistakes on
case study 6 chose the answer that suggests that payment
should be made at the end of the study.
DISCUSSION
The aim of the present study was to assess the knowl-
edge of researchers and IRB/IEC members regarding the
essential ICF elements required by internationally recog-
nized guidelines and regulations. The majority of partici-
pants generally understood the elements (median score = 7
and one-third of participants got a perfect score). However,
there were two elements which caused confusion for a sig-
nificant number of participants. The first is that concerning
a person’s authority to access confidential data. Among the
107 participants, 49 failed to recognize that certain individ-
uals with the responsibility to ensure the quality and validi-
ty of the collected data must have direct access to the
Fig. 1. The data distribution of the participants’ scores. Of
107 participants, the median score was 7
(interquartile, 6–8).
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identity and collected health data of research subjects [3].
The duty of the investigator team is to respect the wishes
of research subjects who grant the team access to their in-
formation. Thus, it is important to specify in the ICF who
else, other than the investigator team, will have access to
the subjects’ confidential information. This piece of infor-
mation is important in obtaining valid consent, as research
subjects may not feel comfortable participating in a partic-
ular study if other people can see their health information.
If this detail is not disclosed, research subjects may incor-
rectly assume that no one but the investigator team can get
access to their confidential data. In this context, an issue
arises when the investigator team allows the monitoring
and/or overseeing team access to the confidential informa-
tion of the subjects. Based on the subject’s assumption, this
would be considered a breach of the confidentiality agree-
ment, in violation of the ethical principle of Respect for
Persons.
The second common mistake made by over one-third
of the participants (38 out of 107) was the requirement of
prorated payment, if any, for research participation. Many
thought that payment should be made at the end of the
study. The ICH GCP [3] requires the sponsor or investiga-
tor team to make a payment, if any, to the subjects in a pro-
rated manner so as to ensure the voluntariness of the
subject’s study participation. In other words, the method of
payment could affect the voluntariness of research sub-
jects. If the payment is made at the end of the study, it
could suppress the desire to withdraw from the study,
thereby decreasing the voluntariness of research participa-
tion. Since voluntariness is one of the three components
emphasized in the Belmont Report [2] as necessary for the
validity of informed consent, the informed consent will be-
come invalid if the component of voluntariness is missing.
To our knowledge, this is the first empirical study to
evaluate researchers’ and IRB/IEC members’ understand-
ing of the essential basic elements required in an ICF. The
two major misunderstandings of the study participants,
who were mainly researchers or IRB/IEC members in
Asia, the Western Pacific and Africa region, raise concern
about the validity of informed consent in research practice
in tropical countries. In order to improve human subject
protection in research in these regions, there is a need to
address these weaknesses. It is the role of researchers as
well as IRB/IEC members to review the validity of an ICF.
As such, proper training in research ethics and clinical
studies that emphasize the application of ethical principles
underlying each required ICF element is recommended.
The researchers and IRB/IEC members should understand
and appreciate the importance of each required element.
Our study has some limitations. First, there was the
potential impact of selection bias, that is, the study partici-
pants might not be representative of researchers and
IRB/IEC members throughout the Asia Pacific and African
Fig. 2. The frequency of incorrect answers for each question. Of the 139 incorrect answers from 107 participants, the two most
common incorrect answers were on the ethical issues of (1) authority of persons who can access the data and (2) the need
for prorated payment, which accounted for 35% (49/139) and 28% (38/139) of all the incorrect answers, respectively. The
participants made a relatively small number of mistakes on the remaining six ethical issues: compensation in case of any
injury during participation (13/139), right of the subjects to withdraw (10/139), confidentiality of the data (10/139), right of
the subjects to refuse (8/139), contact person for more information during the study (7/139), and experimental nature of the
study (4/139).
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regions. The majority of the study participants were attend-
ees of the Forum of Ethical Review Committees and so
may have been more likely to be interested in and knowl-
edgeable about the issue of informed consent, compared to
IRB/IEC members/researchers who do not participate in
the forum. Second, since the questionnaire used in this sur-
vey was in English while the participants came from sever-
al countries in the Asia Pacific and African regions, some
of the participants might have had a limited grasp of
English as it is neither their mother tongue nor an official
language in their countries. Due to the language barrier,
the score of some participants might be compromised. Five
participants whose scores were less than 4 could be re-
sulted from their obstacle to understand the contents of the
questionnaire.
In conclusion, the results of this study suggest that
there is a need to improve training regarding informed con-
sent among researchers and IRB/IEC members, especially
in the Asia Pacific and African regions. The two common
significant mistakes fall under the category of relevant in-
formation for decision making (i.e. persons who are re-
quired by regulation to have access to the confidential
data) and factors affecting voluntariness of research partic-
ipants (i.e. prorated payment for research participation).
The objective of ethical training should not only detail the
required elements and documentation of an ICF, but also
emphasize the importance of valid consent.
ACKNOWLEDGMENTS
We would like to thank all the participants for their
time in answering the questionnaires. We appreciate the
collaboration of the experts from FERCAP who reviewed
the case studies used in this study. We thank Professor
Cristina Torres and Dr. Qi Lu for coordinating the
assessment of the case studies and the conduct of this
study. We thank Professor Kenji Hirayama for making
comments on this study.
CONFLICT OF INTEREST
We declare no conflicts of interest.
REFERENCES
 1. The Nuremberg Code. Trials of War Criminals before the
Nuremberg Military Tribunals under Control Council
Law No. 10: Nuremberg October 1946–April 1949.
Washington: U.S. Government Printing Office (n.d.);
1949. pp 181–182.
 2. The Belmont Report. Ethical principles and guidelines for
the protection of human subjects of research: the Super-
intendent of Documents. Washington, D.C.: U.S. Govern-
ment Printing Office; 20402; 1979.
 3. International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for
Human Use: Good Clinical Practice (E6). Washington,
D.C.: European Medicines Agency (EMEA); 1996.
 4. Cox AC, Fallowfield LJ, Jenkins VA. Communication and
informed consent in phase 1 trials: a review of the litera-
ture. Support Care Cancer 2006; 14: 303–309.
 5. Kass NE, Chaisson L, Taylor HA, et al. Length and com-
plexity of US and international HIV consent forms from
federal HIV network trials. J Gen Intern Med 2011; 26:
1324–1328.
 6. Bhutta ZA. Beyond informed consent. Bull World Health
Organ 2004; 82: 771–777.
 7. Title 45 Code of Federal Regulations, Part 46 Protection
of Human Subjects (45 CFR 46), revised January 15,
2009. Washington, D.C.: U.S. Department of Health and
Human Services.
122 Tropical Medicine and Health Vol.43 No.2, 2015
